OSCR · Oscar Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $11.70B | $9.18B | $5.86B | $3.96B | $462.80M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | - | - | - | - | - |
| SG&A | $2.05B | $1.76B | $339.72M | $309.78M | $166.66M |
| Total Operating Expenses | - | - | - | - | - |
| D&A | $28.89M | $32.15M | $30.69M | $15.28M | $11.29M |
| Operating Income | ($396.36M) | $57.27M | ($235.62M) | ($589.87M) | ($402.27M) |
| Interest Expense | $17.60M | $23.73M | $24.60M | $22.62M | $3.51M |
| Income Tax | $5.61M | $7.30M | $3.29M | ($523.0K) | $1.04M |
| Net Income | ($443.15M) | $25.43M | ($270.73M) | ($606.27M) | ($406.82M) |
| EPS - Basic | ($1.69) | $0.11 | ($1.22) | ($2.85) | ($14.16) |
| EPS - Diluted | ($1.69) | $0.10 | ($1.22) | ($2.85) | ($14.16) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.77B | $1.53B | $1.87B | $1.56B | $336.64M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - |
| Current Assets | $4.61B | $2.85B | $3.06B | $4.12B | $2.31B |
| Total Assets | $6.33B | $4.84B | $3.60B | $4.53B | $3.32B |
| Current Liabilities | $4.86B | $3.46B | $2.43B | $3.26B | $1.85B |
| Long-term Debt | $430.10M | $299.56M | $298.78M | $298.00M | $0 |
| Total Liabilities | $5.34B | $3.82B | $2.80B | $3.63B | $1.93B |
| Stockholders' Equity | $977.65M | $1.01B | $803.97M | $890.38M | $1.39B |
| Retained Earnings | ($3.29B) | ($2.85B) | ($2.88B) | ($2.61B) | ($2.00B) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.09B | $978.19M | ($272.16M) | $380.35M | $222.73M |
| Investing Cash Flow | ($241.06M) | ($1.39B) | $577.19M | ($226.52M) | ($344.71M) |
| Financing Cash Flow | $399.21M | $68.39M | $6.45M | $301.11M | $611.71M |
| CapEx | $36.37M | $27.90M | $25.58M | $29.01M | $14.02M |
| Free Cash Flow | $1.06B | $950.30M | ($297.74M) | $351.34M | $208.71M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | -3.4% | 0.6% | -4.0% | -14.9% | -86.9% |
| EBITDA margin | -3.1% | 1.0% | -3.5% | -14.5% | -84.5% |
| Net margin | -3.8% | 0.3% | -4.6% | -15.3% | -87.9% |
| Free cash flow margin | 9.0% | 10.4% | -5.1% | 8.9% | 45.1% |
| FCF / Net income | -2.39 | 37.37 | 1.10 | -0.58 | -0.51 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | 17.5% | 19.1% | 5.8% | 7.8% | 36.0% |
| Effective tax rate | - | 22.3% | - | - | - |
| Return on assets | -7.0% | 0.5% | -7.5% | -13.4% | -12.2% |
| Return on equity | -45.3% | 2.5% | -33.7% | -68.1% | -29.3% |
| Return on invested capital | -22.2% | 3.4% | -16.9% | -39.2% | -22.9% |
| Liquidity | |||||
| Current ratio | 0.95 | 0.82 | 1.26 | 1.26 | 1.24 |
| Quick ratio | 0.95 | 0.82 | 1.26 | 1.26 | 1.24 |
| Cash ratio | 0.57 | 0.44 | 0.77 | 0.48 | 0.18 |
| Leverage | |||||
| Debt / Equity | 0.44 | 0.30 | 0.37 | 0.33 | 0.00 |
| Debt / Assets | 0.07 | 0.06 | 0.08 | 0.07 | 0.00 |
| Debt / EBITDA | - | 3.35 | - | - | - |
| Interest coverage | -22.5x | 2.4x | -9.6x | -26.1x | -114.5x |
| Equity multiplier | 6.47 | 4.78 | 4.48 | 5.08 | 2.39 |
| Liabilities / Assets | 0.84 | 0.79 | 0.78 | 0.80 | 0.58 |
| Efficiency | |||||
| Asset turnover | 1.85 | 1.90 | 1.63 | 0.88 | 0.14 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | 134.4x | - | - | - |
| P / B | 3.9x | 3.5x | 2.5x | 0.6x | 0.2x |
| P / S | 0.3x | 0.4x | 0.3x | 0.1x | 0.5x |
| EV / EBITDA | - | 26.2x | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | 27.5% | 56.5% | 47.9% | 756.4% | - |
| Revenue CAGR (3y) | 43.5% | 170.7% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 60.1% | -46.6% | - |
| Net income growth (YoY) | - | - | 55.3% | -49.0% | - |
| EPS growth (YoY) | - | - | 57.2% | 79.9% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 11.4% | - | - | 68.3% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -3.5% | 26.1% | -9.7% | -35.8% | - |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.26
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Hospital & Medical Service Plans
Comparing Oscar Health against the 5 most active filers in the same SIC group.